Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD, Food Effect, and CSF Study of Xanamem in Healthy Subjects
NCT02616445Phase 1Completed
- Sponsor
- Actinogen Medical Limited
- Start
- Feb 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of emestedastat in Alzheimer's disease (AD) (3 arms), sponsored by Actinogen Medical Limited. Primary endpoints: Safety and Tolerability of UE2343 at Day 17, Maximum Plasma Concentration at Day 8 and 4 more. Started Feb 2015; status: completed.
02
Drugs
emestedastat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02616445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02616445.